| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/24/2004 | US20040122033 Combination therapy for the treatment of obesity |
| 06/24/2004 | US20040122027 Use of pyridoindolone derivatives for preparing anticancer medicines |
| 06/24/2004 | US20040122024 Effective against mutations; such as 2,3-Dihydro-4-ethyl-1-(3-methylphenylamino)-5-phenyl-1H-imidazole-2-thione |
| 06/24/2004 | US20040122018 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives; use in combination with antineoplastic agents such as cisplatin |
| 06/24/2004 | US20040122017 Melanin concentrating hormone (MCH) modulators; metabolic and eating disorders |
| 06/24/2004 | US20040122011 such as 3-[3-[N-isopropyl-N-(4-methoxyphenyl-sulfonyl)amino]-phenyl]-3-(3-pyridyl)-2(E)-propenohydroxamic acid; for treatment/prevention of neoplasia/inflammation; kits |
| 06/24/2004 | US20040122010 Treatment of neuropathy |
| 06/24/2004 | US20040122000 Inhibitors of aspartyl protease |
| 06/24/2004 | US20040121987 Liposomal analgesic formulation and use |
| 06/24/2004 | US20040121981 Administering therapeutically effective amount of a compound which binds to a galectin |
| 06/24/2004 | US20040121979 Pharmaceutically active uridine esters |
| 06/24/2004 | US20040121975 Hepatitis C virus assays |
| 06/24/2004 | US20040121972 Methylenetetrahydrofolate reductase inhibitors and uses thereof |
| 06/24/2004 | US20040121971 Therapeutic use of tumor necrosis factor-alpha mutein |
| 06/24/2004 | US20040121961 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| 06/24/2004 | US20040121395 Sequence #115 as a target for identifying weight modulating compounds |
| 06/24/2004 | US20040121387 Comprises nucleotide sequences coding caspase 8 inhibitory protein for use in the treatment of alzheimer's, parkinson's, arthritic, septic, cardiovascular, inflammatory, osteoporotic and ischemic reperfusion injuries/disorders |
| 06/24/2004 | US20040121372 Comprises receptors for advanced glycation endproduct polypeptides for use in diagnosis and treatment inflammation, infection, sepsis, autoimmune, atherosclerotic and nervous system disorders |
| 06/24/2004 | US20040121345 Identification of a human n-terminal acetyltransferase gene |
| 06/24/2004 | US20040121028 Plant based agents as bioavailability / bioefficacy enhancers for drugs and nutraceuticals |
| 06/24/2004 | US20040121025 comprises vanadium, ipriflavone, homocysteine inhibiting agent, and an absorbable calcium salt in carrier; side effect reduction |
| 06/24/2004 | US20040121024 comprises glucosamine sulfate, nettle leaf, quercetin, curcumin extract/curcuminoids, selenium, zinc, vitamin C (calcium ascorbate) and grape seed extract |
| 06/24/2004 | US20040121019 Particles comprising a biopolymer which is degradable under the effect of an electromagnetic wave as emitted by a solar radiation |
| 06/24/2004 | US20040121009 Method of modifying the release profile of sustained release compositions |
| 06/24/2004 | US20040121004 protecting the gastrointestinal tract from non-steroidal antiinflammatory drug therapy by administering a NSAID in combination with a buffer and a proton pump inhibitor in a single non-enterically coated dosage form |
| 06/24/2004 | US20040120999 Liposome containing remedy for vascular disease |
| 06/24/2004 | US20040120987 Process and composition for controlling fecal hair excretion and trichobezoar formation |
| 06/24/2004 | US20040120983 Nutritional supplement |
| 06/24/2004 | US20040120952 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 06/24/2004 | US20040120940 Placental alkaline phosphatase to control diabetes |
| 06/24/2004 | US20040120926 Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment |
| 06/24/2004 | US20040120924 Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A |
| 06/24/2004 | DE10259014A1 Antioxidans-Kombinationen mit6,7-disubstituierten 2,2-Dialkylchromanen oder-chromenen Antioxidant combinations mit6,7-disubstituted 2,2-Dialkylchromanen or-chromenes |
| 06/24/2004 | CA2547899A1 Cell-based therapies for ischemia |
| 06/24/2004 | CA2509142A1 Combination for the treatment of adhd |
| 06/24/2004 | CA2508796A1 Topical anti-infective formulations |
| 06/24/2004 | CA2507540A1 Method of reducing toxicity of anticancer agents |
| 06/24/2004 | CA2502625A1 Dioxolane thymine and combinations for use against resistant strains of hiv |
| 06/23/2004 | EP1431399A1 Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| 06/23/2004 | EP1431391A2 Rantes mutants and therapeutic applications thereof |
| 06/23/2004 | EP1430934A1 Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 06/23/2004 | EP1430903A1 Use of proteasome inhibitors for the treatment of viral infections |
| 06/23/2004 | EP1430895A1 Novel substituted benzimidazole dosage forms and method of using same |
| 06/23/2004 | EP1430894A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease |
| 06/23/2004 | EP1430891A1 Oil-acid-emulsion for the treatment of joint diseases and for the stimulation of blood-circulation |
| 06/23/2004 | EP1430882A2 Combinations of antioxidants containing 6,7-disubstituted 2,2-dialkylchromanes or -chromenes |
| 06/23/2004 | EP1430783A1 Oil/fat composition |
| 06/23/2004 | EP1430304A1 Method and agent for diagnosing and treating chronic inflammatory bowel diseases |
| 06/23/2004 | EP1430302A2 Inhibitors of glycosaminoglycans |
| 06/23/2004 | EP1430152A2 Gene and protein relating to hepatocellular carcinoma |
| 06/23/2004 | EP1430144A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 06/23/2004 | EP1430140A2 Isoform-selective inhibitors and activators of pde3 cyclic |
| 06/23/2004 | EP1430132A2 Methods of using 33751, a human potassium channel family member |
| 06/23/2004 | EP1430130A2 Nucleic acid-associated proteins |
| 06/23/2004 | EP1430126A1 Dna sequences for human angiogenesis genes |
| 06/23/2004 | EP1430125A2 Sperm-specific cation channel, and uses therefor |
| 06/23/2004 | EP1430120A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 06/23/2004 | EP1430085A1 Leukocyte inactivation module |
| 06/23/2004 | EP1430045A1 Pyrane derivatives as both ace- and nep-inhibitors |
| 06/23/2004 | EP1430040A1 Benzothiazepine derivatives |
| 06/23/2004 | EP1430017A2 Substituted phenol compounds useful for anesthesia and sedation |
| 06/23/2004 | EP1429845A2 Treatment or prophylaxis of insulin-producing cell graft rejection |
| 06/23/2004 | EP1429843A2 Combination of a pde inhibitor and a leukotriene receptor antagonist |
| 06/23/2004 | EP1429817A1 Porous ceramic composite bone grafts |
| 06/23/2004 | EP1429807A2 Combination of a nsaid and a pde-4 inhibitor |
| 06/23/2004 | EP1429806A2 Extracellular massengers |
| 06/23/2004 | EP1429798A1 Optimal compositions and methods thereof for treating hcv infections |
| 06/23/2004 | EP1429797A2 Diagnosis and treatment of malignant neoplasms |
| 06/23/2004 | EP1429792A1 Strontium compound for treatment of sub-dermal soft tissue pain |
| 06/23/2004 | EP1429784A2 High throughput screening assays using fatty acid synthetic enzymes |
| 06/23/2004 | EP1429779A2 Androstanes as androgen receptor modulators |
| 06/23/2004 | EP1429778A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents |
| 06/23/2004 | EP1429775A1 Methods of treating pulmonary disease |
| 06/23/2004 | EP1429767A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage |
| 06/23/2004 | EP1429766A1 Pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments |
| 06/23/2004 | EP1429764A1 Compositions and methods for the treatment of cancer |
| 06/23/2004 | EP1429760A1 Novel combination |
| 06/23/2004 | EP1429756A2 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| 06/23/2004 | EP1429755A1 Use of vitamin e succinate and antiandrogen combination |
| 06/23/2004 | EP1429749A2 Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| 06/23/2004 | EP1429732A1 A core formulation |
| 06/23/2004 | EP1429730A2 Opioid formulations having reduced potential for abuse |
| 06/23/2004 | EP1429729A1 Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin |
| 06/23/2004 | EP1429725A1 Ophthalmic depot formulations for periocular or subconjunctival administration |
| 06/23/2004 | EP1429723A1 Treating effects of excessive reactive oxygen species |
| 06/23/2004 | EP1429713A2 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy |
| 06/23/2004 | EP1429689A1 Rational drug therapy device and methods |
| 06/23/2004 | EP1429665A2 Composite staple for completing an anastomosis |
| 06/23/2004 | EP1429648A2 METHODS FOR SCREENING FOR SUBSTANCES WHICH INHIBIT FP PROSTANOID RECEPTOR INTERACTION WITH A COMPOUND HAVING PGF 2$g(a)alpha?ACTIVITY AND METHODS OF TREATING CANCER |
| 06/23/2004 | EP1429602A1 Methods for treating disorders using plant extracts |
| 06/23/2004 | EP1265985A4 Pancreatic islet cell growth factors |
| 06/23/2004 | EP1252157B1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 06/23/2004 | EP1024801B1 Method for regulating size and growth of vascularized normal tissue |
| 06/23/2004 | EP0999839B1 Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| 06/23/2004 | EP0930886B1 Formulation for use in the prevention of pathogen induced diseases including hiv and hsv |
| 06/23/2004 | EP0754069B1 Treatment of pulmonary vasoconstriction and asthma |
| 06/23/2004 | EP0750505B1 Immunotherapy of cancer with allogeneic lymphocytes |
| 06/23/2004 | CN1507436A Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers |
| 06/23/2004 | CN1507355A Combination therapy using anti-EGFR antibodies and anti-hormonal agents |
| 06/23/2004 | CN1507354A Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |